PRNP and plasma cell myeloma: From a therapeutic standpoint, the inability of PrP to protect against proteasomal inhibition-induced Caspase 3/7 DEVDase activity implies that up-regulation of PRNP expression would not contribute to chemoresistance in cancers treated with proteasomal inhibitor bortezomib, such as multiple myeloma or mantle cell lymphoma.